* Nuvectis Pharma Inc is expected to show no change in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Nuvectis Pharma Inc is for a loss of 40 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Nuvectis Pharma Inc is $21.00, above its last closing price of $6.76.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.36 -0.36 -0.41 Missed -12.3
Sep. 30 2023 -0.35 -0.34 -0.37 Missed -8.1
Jun. 30 2023 -0.29 -0.29 -0.38 Missed -30.3
Mar. 31 2023 -0.44 -0.44 -0.27 Beat 38.8
Jan. -0.38
1 0001
Sep. 30 2022 -0.27 -0.27 -0.42 Missed -55.6
Jun. 30 2022 -0.22 -0.23 -0.28 Missed -20
Jan. 1 0001 -0.23 -0.23 -0.32 Missed -39.1
This summary was machine generated May 3 at 12:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments